Heron Therapeutics (HRTX) Debt to Equity: 2016-2025
Historic Debt to Equity for Heron Therapeutics (HRTX) over the last 2 years, with Sep 2025 value amounting to $7.22.
- Heron Therapeutics' Debt to Equity rose 1263.54% to $7.22 in Q3 2025 from the same period last year, while for Sep 2025 it was $7.22, marking a year-over-year increase of 1263.54%. This contributed to the annual value of -$0.74 for FY2024, which is 4.13% down from last year.
- Latest data reveals that Heron Therapeutics reported Debt to Equity of $7.22 as of Q3 2025, which was up 914.91% from -$0.89 recorded in Q1 2025.
- Over the past 5 years, Heron Therapeutics' Debt to Equity peaked at $7.22 during Q3 2025, and registered a low of -$0.89 during Q1 2025.
- In the last 3 years, Heron Therapeutics' Debt to Equity had a median value of -$0.72 in 2023 and averaged $0.25.
- Within the past 5 years, the most significant YoY rise in Heron Therapeutics' Debt to Equity was 1,263.54% (2025), while the steepest drop was 22.39% (2025).
- Heron Therapeutics' Debt to Equity (Quarterly) stood at -$0.71 in 2023, then dropped by 4.13% to -$0.74 in 2024, then soared by 1,263.54% to $7.22 in 2025.
- Its Debt to Equity was $7.22 in Q3 2025, compared to -$0.89 in Q1 2025 and -$0.74 in Q4 2024.